Lexatin

Bromazepam, the active ingredient in Lexatin, is a benzodiazepine presented as an oral tablet for oral use. It provides short‑term relief of anxiety symptoms in adults, particularly in generalized anxiety disorder and situational anxiety. GNH USA supplies Lexatin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lexatin (bromazepam) acts on the central nervous system to alleviate anxiety‑related conditions.

Generalized Anxiety Disorder: reduces excessive worry and tension in affected adults. Short‑term Anxiety: provides rapid calming effect for transient anxiety episodes. Pre‑operative Anxiety: helps patients feel calmer before surgical or diagnostic procedures.

Bromazepam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness - Fatigue - Dizziness - Impaired coordination - Memory impairment - Headache

Serious or Rare Side Effects: - Depression or suicidal thoughts - Respiratory depression - Severe allergic reactions (e.g., rash, angioedema) - Paradoxical anxiety or agitation - Withdrawal seizures on abrupt discontinuation - Hepatic dysfunction

Before prescribing or dispensing bromazepam, consider the following safety measures.

Assess renal and hepatic function: adjust use in patients with impairment. Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal. Use caution in elderly: increased sensitivity to sedation and falls. Avoid concomitant CNS depressants: risk of enhanced sedation and respiratory depression. Pregnancy and lactation: consult physician, limited safety data available. Store at room temperature: keep in original container, protect from moisture and light.

Bromazepam can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Opioids: additive respiratory depression. - Barbiturates: profound CNS depression. - Alcohol: increased sedation and impairment.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): risk of serotonin syndrome. - Antihistamines: enhanced drowsiness. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increased bromazepam plasma levels.